Skip to main content

Table 4 Treatments and complications

From: A cross-sectional nationwide survey of congenital and infantile nephrotic syndrome in Japan

 

Finnish-type disease

N = 33

Non-Finnish-type without syndrome

N = 26

Non-Finnish-type with syndrome

N = 24

Medicationsa

   

 Steroids

3/29

(NR, 3)

18/25

(NR, 11; PR, 4; CR, 3)

8/24

(NR, 7; PR, 1)

 Immunosuppressants

3/28

(CSA, NR, 2; PR, 1)

12/25

(NR, 1; PR, 2; CR, 9)

4/24

(NR, 4)

  Immunosuppressant therapy by response

CSA, NR

CSA + MZB, NR

CSA, PR

CSA + TAC + MZB, NR

CSA, PR (n = 2)

CSA, CR (n = 4)

MZB, CR

CSA + MZB, CR

CSA + CP, CR

CSA + MMF + RTX, CR

CSA + MZB + RTX, CR

CSA, NR (n = 4)

Complicationsa

 Thrombosis

5/32

1/26

1/24

 Infections

19/32

7/26

9/24

 Other

8/32

9/26

11/24

  1. Abbreviations: CP cyclophosphamide, CR complete remission, CSA cyclosporine, MMF mycophenolate mofetil, MZB mizoribine, NR no response, PR partial remission, RTX rituximab, TAC tacrolimus
  2. aThe denominator represents the number of patients for whom responses regarding medications and complications were obtained